Patients with haematological malignancies (HM) are particularly vulnerable to severe outcomes from COVID-19, with mortality rates reaching up to 34% in this patient group following COVID-19 infection (1). Although COVID-19 vaccines have been widely effective in reducing severe outcomes in the general population, patients with haematological malignancies often have limited…